COMPACT SIZE
Small enough to fit in the palm of the hand.
Learn how AbbVie could help you save on SKYRIZI.
Call 1.866.SKYRIZI or click tap to learn more ▸
Make SKYRIZI part of your routine with at-home dosing every 8 weeks, after a total of 3 starter doses through a vein in the arm (intravenous infusion) and proper training from your healthcare professional.
600 mg intravenous infusion per dose
There are different kinds of places where you might get your infusions—like your doctor’s office, a hospital, or an infusion center. Infusions can take up to 2 hours to receive.
180 mg/1.2 mL or 360 mg/2.4 mL subcutaneous injection via OBI
You should receive your first treatment using the OBI under the supervision of a qualified health care professional so that you can be properly trained for using it on your own at home. They will help you choose an injection site and guide you on the proper injection technique.
Adults with Crohn’s disease will receive their starter doses with SKYRIZI through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. After completing the starter doses, patients will receive SKYRIZI as an injection under the skin (subcutaneous injection) using the prefilled cartridge with the On-Body Injector (OBI). Your doctor will decide what maintenance dose is right for you.
See the SKYRIZI “Instructions for Use” for the full set of detailed instructions on the preparation and administration of SKYRIZI.
And, after your healthcare professional has shown you how to administer your at-home treatment with the SKYRIZI OBI, watch this video if you ever need a refresher.
1
PREPARE
Gather alcohol wipes, gauze pads or cotton balls, and sharps disposal container.
2
PICK
Pick a place on the thigh or abdomen to inject.
3
PEEL
Peel the 2 green pull tabs to reveal the adhesive without touching the needle.
4
PLACE
Place the OBI onto the skin. Ensure that the status light is visible.
5
PRESS
Press and release the gray start button to begin. A flashing green light will appear. When the injection is complete the green light goes solid.
An OBI, or On-Body Injector is a single-use injector with a prefilled cartridge. It's a NEW way to treat moderate to severe Crohn’s that's been designed with you in mind.
COMPACT SIZE
Small enough to fit in the palm of the hand.
HIDDEN NEEDLE
Discreet injection so you don’t see the needle.
AUDIO AND VISUAL CUES
Notifies when full dose has been delivered.
HANDS-FREE
While adhered to the body and after activation. Moderate physical activities can be done such as walking, reaching, and bending.
DOSE DELIVERED IN 5 MINUTES
Completes the injection in set time after preparation and application are complete.
In a survey of the SKYRIZI On-Body Injector (OBI), patient-reported experience was collected using a Self-Injection Assessment Questionnaire (SIAQ). Patients were given the questionnaire after injection training by a healthcare provider (HCP) and following their first self-injection. 42 out of 45 patients reported the OBI was either “easy” or “very easy” to use.
HOW TO USE SKYRIZI: See the detailed “Instructions for Use” that comes with SKYRIZI for information on how to prepare and inject a dose of SKYRIZI, and how to properly throw away (dispose of) a used SKYRIZI prefilled cartridge with On-Body Injector. Before self-injecting with SKYRIZI prefilled cartridge with On-Body Injector, your healthcare provider should show you how to inject SKYRIZI.
Skyrizi Complete is dedicated to providing personalized support at every step of your treatment.
Watch a video to learn how SKYRIZI specifically targets the IL-23 protein to help reduce the excess inflammation that can contribute to Crohn’s symptoms.
Watch a video to learn how SKYRIZI specifically targets the IL-23 protein to help reduce the excess inflammation that can contribute to Crohn’s disease.
Up Next
Consider the benefits and risks of taking SKYRIZI to make an informed treatment choice with your doctor.
Recommended for You
See how SKYRIZI can provide symptom relief, remission, and endoscopic improvement.
SKYRIZI is a prescription medicine used to treat moderate to severe Crohn's disease in adults.
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems in Crohn's disease: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
SKYRIZI is a prescription medicine used to treat adults with:
US-SKZ-240089
Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.
Legal Notices/Privacy Policy. Copyright 2023, AbbVie Inc., North Chicago, Illinois, U.S.A. If you have any questions about AbbVie’s SKYRIZI.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.